While great strides are being made in oncology, several important areas remain elusive. These are important biological targets impervious to traditional drug discovery approaches.
One of these, and one that is enormously important, is cancer’s ability to reawaken normally turned off embryonic stem cell pathways (ESCPs) for its own purposes.
These ESCPs power our growth and maturation as children, but as adults, are normally turned off.
Many cancers, as we treat them with the latest and greatest immune oncology therapeutics, targeted therapeutics, classical chemotherapy, and radiation, will reactivate these ESCPs and use them as resistance pathways. This defeats the therapies we use and allows the cancers to continue to grow, metastasize, and proliferate, leading to patient death.
The most important of these ESCPs is the Wingless Related Integration Site (WNT) Pathway. It was first discovered in 1982, and then was the subject of a Nobel Prize in 1992. The oncogenetic event of the WNT pathway is its final protein, beta catenin, entering the nucleus of the cell and driving transcription of many of the worst oncogenes.
Beta Cat has the first and only potent and specific inhibitor of beta catenin: Tegavivint (BC-2059).
Should Tegavivint achieve its promise, it may be broadly used across many solid tumors and hematological malignancies where beta catenin is defeating cancer therapies and supporting tumor proliferation.
There are several orphan, accelerated approval indications where Tegavivint is very effective in pre-clinical models which may allow early approval and provide therapy for diseases with tremendous unmet medical needs.